{"id":"W4388534086","doi":"10.1016/j.annonc.2023.10.129","title":"Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","year":2023,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; INCLIVA Instituto de Investigación Sanitaria; Servier; European Society for Medical Oncology; Astellas Pharma; Sierra Oncology; Incyte; Sociedad Española de Oncología Médica; BeiGene; Natera; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Amgen","keywords":"Medicine; Colorectal cancer; Bevacizumab; Internal medicine; Oncology; Oxaliplatin; Irinotecan; Guideline; Cancer; Hazard ratio; Chemotherapy regimen; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003756166,0.0007888887,0.002336488,0.0002784139,0.0001928434,0.00001936057,0.0002042861,0.000539572,0.0006007928],"category_scores_gemma":[0.0002643407,0.0004999544,0.0005697139,0.0004726426,0.0002028891,0.00008165882,0.000103406,0.0004905366,0.00001425188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00238894,"about_ca_system_score_gemma":0.001562392,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03260328,"about_ca_topic_score_gemma":0.09148731,"domain_scores_codex":[0.996239,0.0003421,0.001366082,0.0009286373,0.0002967274,0.0008274695],"domain_scores_gemma":[0.9952797,0.002824462,0.0008926551,0.0003190483,0.0005879626,0.00009618955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003799768,0.001130079,0.004203159,0.00007891596,0.00565926,0.0002559545,0.002059009,0.0002081971,0.0003162399,0.00000286522,0.7072278,0.2750588],"study_design_scores_gemma":[0.007324152,0.02064915,0.01072733,0.0004270034,0.00229298,0.00001284205,0.0005963093,0.0007461054,0.002684179,0.000130853,0.9539459,0.000463232],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.2740596,0.004458699,0.00001213225,0.7080429,0.001753343,0.004642152,0.006264696,0.0001097186,0.0006568579],"genre_scores_gemma":[0.1795901,0.1352161,0.003401707,0.5576154,0.0123889,0.05607023,0.04199838,0.0008075184,0.01291172],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.2745956,"threshold_uncertainty_score":0.9997452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1360276790511177,"score_gpt":0.4430559919145119,"score_spread":0.3070283128633943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}